Skip to main content
OpenTrials
Completed

NCT Number: NCT07686991

Cardiovascular Risk in Patients With Takayasu Arteritis: A Nationwide Population-Based Cohort Study

This nationwide observational cohort study compares the risk of major adverse cardiovascular events (MACE) and territory-specific arterial complications between patients with incident Takayasu arteritis and matched general-population controls, and identifies determinants of MACE within the Takayasu arteritis population, including cumulative glucocorticoid exposure, using the French National Health Data System (SNDS).

Completed

Looking for future studies?

Notify Me

Key information

Age range

15 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

APHP_ Hôpital Pitié-Salpêtrière, Paris, France

Loading trial locations.

About this study

Study Design and Data Source This is a retrospective nationwide cohort study using the SNDS database covering approximately 99% of the French population. All patients aged 15 to 60 years with an incident hospital diagnosis of Takayasu arteritis (ICD-10 M31.4, recorded as a principal, related, or associated diagnosis; validated algorithm with positive predictive value 93.9%) between 2010 and 2024 were identified and matched without replacement to up to four general-population controls Statistical Analysis Cumulative incidence was estimated as one minus the Kaplan-Meier estimate, with 95% confidence intervals. Hazard ratios comparing patients with Takayasu arteritis to matched controls were estimated from Cox proportional-hazards models stratified on the matched set. For non-fatal outcomes, competing-risk analyses treating death as a competing event were performed (Fine-Gray subdistribution hazard ratios and Aalen-Johansen cumulative incidence functions). Within the Takayasu arteritis cohort, cumulative prednisone-equivalent glucocorticoid dose was modelled as a time-dependent covariate in multivariable Cox models adjusted for cardiovascular and disease-related factors.

Outcomes The primary outcome was the first major adverse cardiovascular event (MACE), a composite of coronary event (myocardial infarction or unstable angina), ischemic stroke, or all-cause death. Secondary outcomes included the individual MACE components and territory-specific arterial events: aortic events, visceral artery events, and major adverse limb events.

Regulatory Compliance This study was conducted using the SNDS through the permanent access granted to Assistance Publique - Hôpitaux de Paris (AP-HP), in accordance with French Decree No. 2016-1871 and French Public Health Code (Art. R. 1461-13 and 14). The study was registered in the AP-HP internal registry of research projects before initiation. In compliance with the GDPR and French regulations, individual informed consent was not required as all data were fully anonymized

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 15 to 60 years Cases: incident hospital diagnosis of Takayasu arteritis (ICD-10 M31.4) recorded as principal, related, or associated diagnosis between 2010 and 2024 Cases matched 4:1 to general-population controls (exact on sex and region; calipers on year of birth and propensity-score logit) Controls: alive and active in the database at the index date (≥1 reimbursed contact in the prior 365 days), residing in the same region, with no recorded Takayasu arteritis diagnosis

Exclusion criteria

Cases who could not be matched to at least four eligible general-population controls Age outside the 15 to 60 years range at the index date

Treatment and study plan

Primary outcomes

  1. Major Adverse Cardiovascular Events (MACE)

    Time frame: Up to 15 years (January 2010 to December 2024)

    Major Adverse Cardiovascular Events (MACE) Composite of myocardial infarction, ischemic stroke, or all-cause death

Secondary outcomes

  1. Coronary events

    Time frame: Time Frame: Up to 15 years (2010-2024)

    Coronary events (myocardial infarction or unstable angina)

  2. Ischemic stroke

    Time frame: Time Frame: Up to 15 years (2010-2024)

    Ischemic stroke

  3. All-cause mortality

    Time frame: Time Frame: Up to 15 years (2010-2024)

    All-cause mortality

  4. Aortic events

    Time frame: Up to 15 years (2010-2024)

    Aortic events (aortic dissection or aneurysm, or thoracic/abdominal aortic surgical or endovascular procedure) Time Frame: Up to 15 years (2010-2024)

  5. Visceral artery events

    Time frame: Up to 15 years (2010-2024)

    Visceral artery events (digestive or renal artery dissection, aneurysm, or revascularization)

  6. Major adverse limb events

    Time frame: Up to 15 years (2010-2024)

    Major adverse limb events (lower-limb revascularization or major amputation)

Sponsors and collaborators

Lead sponsor

Groupe français d'étude des Maladies Inflammatoires de loeil

Other

Registry information

Official study title

Major Adverse Cardiovascular Events and Territory-Specific Arterial Complications in Patients With Takayasu Arteritis Compared With Matched General-Population Controls: A Nationwide Cohort Study Using the French SNDS

Acronym: TAK-CV-2026

Important dates

Study start
2010
Primary completion
2024
Study completion
2024
First posted
Jul 7, 2026
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.